| Literature DB >> 35949664 |
Arif Hakan Onder1, Goksel Bengi2, Mucahit Ozbilgin3, Tarkan Unek3, Ibrahim Astarcioglu3, Mesut Akarsu2.
Abstract
Background and Aim: Liver transplantation is performed in increasing numbers due to advances in surgical techniques and the introduction of diverse immunosuppressive drugs. The present study aims to analyze the effects of socioeconomic status and education level on patient and graft survival, in addition to all these factors. Material andEntities:
Keywords: Liver transplantation; patient compliance; patient survival
Year: 2020 PMID: 35949664 PMCID: PMC9344369 DOI: 10.14744/hf.2020.0003
Source DB: PubMed Journal: Hepatol Forum ISSN: 2757-7392
Figure 1Distribution of patient numbers according to regions.
Figure 2Distribution of places born and lived according to developmen- tal status.
Correlation between the SES of the individuals and SES of places born and lived
| Hollingshead index | Total | p | ||
|---|---|---|---|---|
| Low | High | |||
| Birth place | ||||
| Low | 125 | 24 | 149 | |
| High | 91 | 38 | 129 | 0.008 |
| Total | 216 | 62 | 278 | |
| Place lived | ||||
| Low | 87 | 16 | 103 | |
| High | 129 | 46 | 175 | 0.038 |
| Total | 216 | 62 | 278 | |
Correlation of the patient compliance with the developmental level of the places born and lived
| Developmental status of place lived | Developmental status of birthplace | |||||||
|---|---|---|---|---|---|---|---|---|
| H | L | p | OR | H | L | p | OR | |
| Lifestyle incompliance | ||||||||
| Y | 72.6% (98) | 44.8% (73) | 42.2% (57) | 57.8% (78) | ||||
| N | 53.8% (77) | 46.2% (66) | 0.001 | 1.5 | 50.3% (72) | 49.7% (71) | 0.174 | 1.3 |
| Weight control incompliance | ||||||||
| Y | 73.9% (85) | 26.1% (30) | 42.6% (49) | 57.4% (66) | ||||
| N | 55.2% (90) | 44.8% (73) | 0.001 | 1.6 | 49.1% (80) | 50.9% (83) | 0.287 | 1.2 |
| Visit incompliance | ||||||||
| Y | 58.6% (68) | 41.4% (48) | 0.206 | 1.3 | 39.7% (46) | 60.3% (70) | 0.056 | 1.5 |
| N | 66% (107) | 34.0% (55) | 51.2% (83) | 48.8% (79) | ||||
| <24 month visit loss | ||||||||
| Y | 50.8% (30) | 49.2% (29) | 0.030 | 1.8 | 37.3% (22) | 62.7% (37) | 0.114 | 1.6 |
| N | 66.2% (140) | 33.8% (74) | 48.9% (107) | 51.1% (112) | ||||
| ≥2 visit loss | ||||||||
| Y | 58.1% (25) | 41.9% (18) | 32.6% (14) | 67.4% (29) | ||||
| N | 63.8% (150) | 36.2% (85) | 0.477 | 1.2 | 48.9% (115) | 51.1% (120) | 0.048 | 1.9 |
Data about patient and graft survival, patient compliance and complications concerning educational and vocational status in liver transplant recipients
| ES | VS | |||||
|---|---|---|---|---|---|---|
| Low (n=201) | High (n=77) | p | Low (n=211) | High (n=67) | p | |
| Graft failure (%/n) | 18.9 (38) | 20.8 (16) | 0.724 | 19.9 (42) | 17.9 (12) | 0.719 |
| Clinical | 3.0 (6) | 6.5 (5) | 0.180 | 3.8 (8) | 4.5 (3) | 0.730 |
| Pathologic | 8.5 (17) | 11.7 (9) | 0.408 | 8.5 (18) | 11.9 (8) | 0.404 |
| Clinicopathologic | 22.4 (45) | 23.4 (18) | 0.860 | 23.7 (50) | 19.4 (13) | 0.465 |
| Death (%/n) | 9.0 (18) | 6.5 (5) | 0.505 | 9.5 (20) | 4.5 (3) | 0.195 |
| Died >100 days | 10.0 (20) | 7.8 (6) | 0.580 | 10.0 (21) | 7.5 (5) | 0.542 |
| Cause of death (%/n) | 7.0 (14) | 5.2 (4) | 0.787 | 7.6 (16) | 3.0 (2) | 0.258 |
| Infection | 2.5 (5) | 3.9 (3) | 0.689 | 2.8 (6) | 3.0 (2) | 1.000 |
| Cardiac | 3.0 (6) | 6.5 (5) | 0.184 | 3.3 (7) | 6.0 (4) | 0.332 |
| Respiratory | 70.6 (142) | 61.0 (47) | 0.124 | 70.1 (148) | 61.2 (41) | 0.171 |
| Other | 15.9 (32) | 6.5 (5) | 0.038 | 15.2 (32) | 7.5 (5) | 0.106 |
| Patient incomplian t(%/n) | 44.8 (90) | 33.8 (26) | 0.096 | 45.0 (95) | 31.3 (21) | 0.048 |
| Drugs | 22.9 (46) | 16.9 (13) | 0.273 | 21.8 (46) | 19.4 (13) | 0.676 |
| Visits | 21.9 (44) | 16.9 (13) | 0.355 | 23.2 (49) | 11.9 (8) | 0.046 |
| <24months | 27.9 (56) | 22.1 (17) | 0.327 | 26.1 (55) | 26.9 (18) | 0.897 |
| >24months | 16.9 (34) | 11.7 (9) | 0.281 | 19.0 (40) | 4.5 (3) | 0.004 |
| 1visit | 49.3 (99) | 46.8 (36) | 0.709 | 47.9 (101) | 50.7 (34) | 0.681 |
| ≥2visits | 41.8 (84) | 40.3 (31) | 0.817 | 40.8 (86) | 43.3 (29) | 0.715 |
| Lifestyle weight | 11.4 (23) | 10.4 (8) | 0.803 | 11.4 (24) | 10.4 (7) | 0.834 |
| Smoking | 3.0 (6) | 6.5 (5) | 0.184 | 2.8 (6) | 7.5 (5) | 0.091 |
| Alcohol | 87.1 (175) | 87.0 (67) | 0.991 | 85.8 (181) | 91.0 (61) | 0.264 |
| Complications (%/n) | 16.9 (34) | 18.2 (14) | 0.803 | 16.6 (35) | 19.4 (13) | 0.595 |
| Surgical | 58.2 (117) | 62.3 (48) | 0.531 | 57.3 (121) | 65.7 (44) | 0.227 |
| Metabolic | 18.9 (38) | 23.4 (18) | 0.406 | 19.4 (41) | 22.4 (15) | 0.599 |
| Neurologic | 24.9 (50) | 24.7 (19) | 0.972 | 26.1 (55) | 20.9 (14) | 0.393 |
| Cardiac | 64.7 (130) | 59.7 (46) | 0.445 | 64.0 (135) | 61.2 (41) | 0.680 |
| Infection | 7.5 (15) | 9.1 (7) | 0.653 | 7.1 (15) | 9.0 (6) | 0.618 |
| Neoplasia | 64.7 (130) | 58.4 (45) | 0.335 | 64.5 (136) | 58.2 (39) | 0.356 |
| Other | 21.4 (43) | 22.1 (17) | 0.901 | 22.7 (48) | 17.9 (12) | 0.402 |
| Vascular | 57.7 (116) | 53.2 (41) | 0.502 | 58.3 (123) | 50.7 (34) | 0.278 |
| GIS | 5.0 (10) | 6.5 (5) | 0.566 | 5.7 (12) | 4.5 (3) | 1.000 |
| Rheumatologic | 20.4 (41) | 18.2 (14) | 0.678 | 19.4 (41) | 20.9 (14) | 0.793 |
| Biliary | 10.0 (20) | 7.8 (6) | 0.580 | 10.0 (21) | 7.5 (5) | 0.542 |
| Incisional hernia (%/n) | 60.7 (122) | 51.9 (40) | 0.186 | 59.2 (125) | 55.2 (37) | 0.448 |
| Less work act. (%/n) | 42.5±25.8 (months) | 45.2±26.9 (months) | 0.369 | 42.7±26.3 (months) | 44.9±25.5 (months) | 0.525 |
| Follow up (days/months) (mean±SD) | 1275.3±775.1 (days) | 1357.0±808.0 (days) | 0.372 | 1281.7±790.5 (days) | 1348.9±765.6 (days) | 0.525 |
| Primary (%/n) recurrent disease | 10.0 (20) | 18.2 (14) | 0.061 | 10.4 (22) | 17.9 (12) | 0.103 |
| Post-transplant(%/n) serology(+) continue | 12.4 (25) | 18.2 (14) | 0.217 | 12.1 (27) | 22.2 (12) | 0.053 |
| Immunosup (%/n). | 10.4 (21) | 13.0 (10) | 0.547 | 10.4 (22) | 13.4 (9) | 0.496 |
| ineffective/adv. eff | 8.0 (16) | 3.9 (3) | 0.229 | 7.6 (16) | 4.5 (3) | 0.579 |
| Reperfusion synd. Preservation damage | 3.5 (7) | 2.6 (2) | 1.000 | 3.8 (8) | 1.5 (1) | 0.692 |
Data about the correlation between SES and patient and graft survival, patient compliance and complications in liver transplant recipients
| SES | |||
|---|---|---|---|
| Low (n=216) | High (n=62) | p | |
| Graft failure. (%/n) | |||
| Clinical | 19.4 (42) | 19.4 (12) | 0.987 |
| Pathologic | 3.7 (8) | 4.8 (3) | 0.713 |
| Clinicopathologic | 9.3 (20) | 14.5 (9) | 0.233 |
| Death (%/n) | 23.6 (51) | 19.4 (12) | 0.480 |
| Died >100 days | 9.3 (20) | 4.8 (3) | 0.265 |
| Cause of death (%/n) | 10.2 (22) | 6.5 (4) | 0.373 |
| Infection | 7.4 (16) | 3.2 (6) | 0.380 |
| Cardiac | 2.8 (6) | 3.2 (2) | 1.000 |
| Respiratory | 3.2 (7) | 6.5 (4) | 0.271 |
| Other | |||
| Complications(%/n) | 85.6 (185) | 91.9 (57) | 0.194 |
| Surgical | 17.1 (37) | 17.7 (11) | 0.910 |
| Metabolic | 57.4 (124) | 66.1 (41) | 0.218 |
| Neurologic | 19.0 (41) | 24.2 (15) | 0.367 |
| Cardiac | 25.9 (56) | 21.0 (13) | 0.426 |
| Infection | 63.4 (137) | 62.9 (39) | 0.940 |
| Neoplasia | 6.9 (15) | 9.7 (6) | 0.470 |
| Other | 64.8 (140) | 56.5 (35) | 0.229 |
| Vascular | 22.2 (48) | 19.4 (12) | 0.629 |
| GIS | 58.3 (126) | 50.0 (31) | 0.243 |
| Rheumatologic | 6.0 (13) | 3.2 (2) | 0.534 |
| Biliary | 19.0 (41) | 22.6 (14) | 0.531 |
| Incisional hernia (%/n) | 9.7 (21) | 8.1 (5) | 0.693 |
| Less work act.(%/n) | 60.2 (130) | 51.6 (32) | 0.228 |
| Follow up (days/months) (meant±SD) | 1283.7±788.4 (0–2679) | 1347.5±771.6 (0–2552) | 0.569 |
| Primary (%/n) recurrent disease | 42.7±26.2 (0–89.3) | 44.9±25.7 (0–85.1) | 0.571 |
| Post-transplant (%/n) serology (+) continue | 10.2 (22) | 19.4 (12) | 0.052 |
| Immunosup (%/n) | 12.0 (26) | 21.0 (13) | 0.074 |
| ineffective/adv eff | 10.6 (23) | 12.9 (8) | 0.619 |
| Reperfusion synd. | 7.4 (16) | 4.8 (3) | 0.581 |
| Preservation damage | 3.7 (8) | 1.6 (1) | 0.689 |
Data with significant correlation with rejection
| Rejection | p | OR | t | ||
|---|---|---|---|---|---|
| Yes | No | ||||
| “Other’’ etiologic causes | 34.5% (10) | 12.0% (30) | 0.003 | 3.8 | 40 (14.4%) |
| Preservation damage | 10.3% (3) | 2.4% (6) | 0.022 | 4.6 | 9 (3.2%) |
| Digestive tract complication | 79.3% (43) | 53.8% (134) | 0.009 | 3.2 | 157 (56.5%) |
| Viral hepatitis recurrence | 30.8% (8) | 10.3% (26) | 0.043 | 3.8 | 34 (12.2%) |
| Decreased work activity | 75.9% (22) | 56.2% (140) | 0.042 | 2.4 | 162 (58.3%) |
| Gender female | 50.0% (13) | 29.8% (75) | 0.035 | 2.3 | 88 (31.7%) |
Figure 3Survival curve concerning education level.